Wednesday, July 8, 2026

pharma · Coronary Artery Bypass Grafting · Hypertension Pulmonary Secondary · TENX

TENAX THERAPEUTICS

TENAX THERAPEUTICS clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Chapel Hill, USA HQ
19 Employees
Public company Type
TENX · NYSE Ticker
Company details
Status
Public
HQ
Chapel Hill, USA
Employees
19
Programs
7
Drugs
2
Patents
4
Intelligence · Clinical Programs

TENAX THERAPEUTICS projects

3 ClinicalTrials.gov programs sponsored by TENAX THERAPEUTICS.

TENAX THERAPEUTICS has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Levosimendan

    TENAX THERAPEUTICS, INC.

    Hypertension Pulmonary Secondary

    phase 2 small molecule completed

    1 trial
  2. Levosimendan

    TENAX THERAPEUTICS, INC.

    Hypertension Pulmonary Secondary Heart Failure

    phase 2 small molecule completed

    1 trial
  3. Oxycyte

    TENAX THERAPEUTICS, INC.

    Traumatic Brain Injury

    phase 2 small molecule terminated

    2 trials

Frequently asked questions

How many clinical projects does TENAX THERAPEUTICS have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.